Back to Search
Start Over
Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects.
- Source :
-
Muscle & nerve [Muscle Nerve] 2000 Feb; Vol. 23 (2), pp. 189-92. - Publication Year :
- 2000
-
Abstract
- This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 microg/kg/day. No serious or life-threatening adverse events occurred. The most frequently recorded adverse effects were mild injection-site pain, diarrhea, and elevation of liver function tests. No change in neurologic function was noted with these dosing regimens. We conclude that r-metHuNT3 is safe and well tolerated in the dosages used in this study.<br /> (Copyright 2000 John Wiley & Sons, Inc.)
- Subjects :
- Adult
Brain-Derived Neurotrophic Factor administration & dosage
Brain-Derived Neurotrophic Factor pharmacokinetics
Diarrhea chemically induced
Double-Blind Method
Female
Humans
Injections, Subcutaneous
Liver Function Tests
Male
Neurotrophin 3 administration & dosage
Neurotrophin 3 pharmacokinetics
Pain chemically induced
Physical Examination
Recombinant Proteins administration & dosage
Recombinant Proteins pharmacokinetics
Recombinant Proteins toxicity
Brain-Derived Neurotrophic Factor toxicity
Neurotrophin 3 toxicity
Subjects
Details
- Language :
- English
- ISSN :
- 0148-639X
- Volume :
- 23
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Muscle & nerve
- Publication Type :
- Academic Journal
- Accession number :
- 10639609
- Full Text :
- https://doi.org/10.1002/(sici)1097-4598(200002)23:2<189::aid-mus7>3.0.co;2-8